Lilly's Basaglar Becomes A Blockbuster
Global Sales Of Follow-On Insulin Glargine Grow By Two-Fifths In 2019
Quarterly global Basaglar sales rose above $300m for the first time in the fourth quarter of 2019, with full-year turnover pushing the insulin glargine hybrid well into blockbuster territory.